Future implications: Compliance and failure with antiretroviral treatment

Journal of Postgraduate Medicine

Volumn 52, Issue 3, 2006, Pages 197-200

  Patel, Atul ^a   Patel, K ^a  

^a Infectious Diseases Clinic   (India)

Author keywords

Adherence; Antiretroviral treatment; Non nucleoside reverse transcriptase inhibitor; Protease inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG POTENCY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NAUSEA; PATIENT COMPLIANCE; PATIENT MONITORING; TREATMENT PLANNING; VIRUS REPLICATION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 33746595255     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292:191-201.
2. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virologic response to potent antiretroviral therapy. AIDS 1999;13:1873-80.
3. Raboud JM, Harris M, Rae S, Montaner JS. Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy. HIV Med 2002;3:118-24.
4. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 23, 2004. and October 6, 2005. Available at: http://aidsinfo.nih.gov.
5. Markowitz M, Mohri H, Mehandru S, Shet A, Berry L, Kalyanaraman R, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005;365:1031-8.
6. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
7. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003;17:1925-32.
8. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005;191:339-47.
9. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004;53:696-9.
10. Cheever L. Forum for Collaborative HIV Research. What do we know about adherence levels in different populations? Adherence to HIV therapy: Building a bridge to success. Available at http://www.gwhealthpolicy.org. Washington, D.C: 1999. p. 10.
11. Greenberg RN. Overview of patient compliance with medication dosing: A literature review. Clin Ther 1984;6:592-9.
12. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurs AIDS Care 1997;8:43-54.
13. Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002;16:2175-82.
14. Riley ED, Wu AW, Perry S, Clark RA, Moss AR, Crane J, et al. Depression and drug use impact health status among marginally housed HIV-infected individuals. AIDS Patient Care STDs 2003;17:401-6.
15. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17:377-81.
16. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr 2000;23:396-404.
17. Bogart LM, Catz SL, Kelly JA, Benotsch EG. Factors influencing physicians' judgments of adherence and treatment decisions for patients with HIV disease. Med Decis Making 2001;21:28-36.
18. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients: ICONA Study Group. AIDS 2000;14:499-507.
19. th International AIDS Conference: Durban, South Africa; 2000 Abstract WePpB1380.
20. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:117-25.
21. Stone VE, Hogan JW, Schuman P, Rompalo AM, Howard AA, Korkontzelou C, et al. Antiretroviral regimen complexity, self-reported adherence and HIV patients' understanding of their regimens: Survey of women in the HER study. J Acquir Immune Defic Syndr 2001;28:124-31.
22. Jordan J, Carranza Rosenzweig J, Pathak D, Pilon T. Perceived influence of regimen characteristics on adherence. Program and abstracts of the 5th International Congress on Drug Therapy in HIV Infection: Glasgow, Scotland; 2000.
23. Stone VE, Jordan J, Tolson J, Pilon T. Potential impact of once-daily regimens on adherence to HAART. Program and abstract of the 40th Annual Meeting of the Infectious Diseases Society of America: Chicago, Illinois; 2002.
24. Miller LG, Liu H, Hays RD, Golin CE, Ye Z, Beck CK, et al. Knowledge of antiretroviral regimen dosing and adherence: a longitudinal study. Clin Infect Dis 2003;36:514-8.
25. Williams A, Friedland G. Adherence, compliance and HAART. AIDS Clin Care 1997;9:51-4,58.
26. Fowler ME. Recognizing the phenomenon of readiness: Concept analysis and case study. J Assoc Nurses AIDS Care 1998;9:72-6.
27. CDC. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998;47:1-41.
28. McPherson-Baker S, Malow RM, Penedo F, Jones DL, Schneiderman N, Klimas NG. Enhancing adherence to combination antiretroviral therapy in non-adherent HIV-positive men. AIDS Care 2000;12:399-404.